Prognostic factors value of germline and somatic brca in patients undergoing surgery for recurrent ovarian cancer with liver metastases

Valerio Gallotta*, Caterina Conte, Marco D'Indinosante, Ettore Capoluongo, Angelo Minucci, Agostino Maria De Rose, Francesco Ardito, Felice Giuliante, Andrea Di Giorgio, Gian Franco Zannoni, Anna Fagotti, Christian Margreiter, Giovanni Scambia, Maria Gabriella Ferrandina

*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivistaArticolo in rivista

14 Citazioni (Scopus)


Objective: To describe accurately the oncological outcomes after hepatic resection (HR) in recurrent ovarian carcinoma (ROC) evaluating clinic-pathological variables and mutational status of BRCA1/2. Although HR is considered a challenging situation in ROC patients, assessment of BRCA1/2 mutational status seems to have a relevant clinical value to guide surgical therapy. Methods: Patients who underwent HR for ROC at the Catholic University of Rome, between June 2012 and October 2017 were included. Exclusion criteria were represented by extra-abdominal disease and presence of diffuse peritoneal carcinomatosis requiring more than 2 bowel resections. Details relative to HR were collected and BRCA analysis was performed. Predictive factors of post-HR progression free survival (PHR-PFS) were assessed by univariate analyses using Cox-proportional hazard regression models. Results: Thirty-four patients undewent HR within secondary cytoreductive surgery (SCS). Six patients (17.6%) presented with hepatic relapse only, while the remaining 28 patients (82.4%) had concomitant extra-hepatic disease. In the whole series, the 3-yr PHR-PFS was 49.1% and the 3-yr post-HR overall survival was 72.9%. Univariate analysis of variables conditioning PHR-PFS showed that only BRCA mutational status played a statistically significant favourable role: the 3-yr PHR-PFS rate was 81.0% in BRCA mutated patient compared to 15.2% in wild type ones (p value: 0.001). Conclusions: Our clinical analyses suggest that in ROC patients with liver disease the assessment of germline and somatic BRCA mutational status can help to select patients elegible for SCS.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaEuropean Journal of Surgical Oncology
Stato di pubblicazionePubblicato - 2019


  • BRCA gene mutational status
  • Hepatic metastasis
  • Personalized medicine
  • Recurrent ovarian cancer
  • Secondary cytoreduction


Entra nei temi di ricerca di 'Prognostic factors value of germline and somatic brca in patients undergoing surgery for recurrent ovarian cancer with liver metastases'. Insieme formano una fingerprint unica.

Cita questo